Reviva Pharmaceuticals Holdings Inc - Asset Resilience Ratio
Reviva Pharmaceuticals Holdings Inc (RVPHW) has an Asset Resilience Ratio of 100.00% as of June 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RVPHW financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2018)
This chart shows how Reviva Pharmaceuticals Holdings Inc's Asset Resilience Ratio has changed over time. See Reviva Pharmaceuticals Holdings Inc balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Reviva Pharmaceuticals Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Reviva Pharmaceuticals Holdings Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $34.22 Million | 100.0% |
| Total Liquid Assets | $34.22 Million | 100.00% |
Asset Resilience Insights
- Very High Liquidity: Reviva Pharmaceuticals Holdings Inc maintains exceptional liquid asset reserves at 100.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Reviva Pharmaceuticals Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Reviva Pharmaceuticals Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for Reviva Pharmaceuticals Holdings Inc (2018–2018)
The table below shows the annual Asset Resilience Ratio data for Reviva Pharmaceuticals Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 100.00% | $65.24 Million | $65.24 Million | -- |
About Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, i… Read more